Antibody profiling for protein drug development and clinical development

Functional Protein Microarrays in Drug Discovery

Volumn , Issue , 2007, Pages 275-300

  Herrmann, Steve H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890504216     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (168)

1. Carter, P.J., Potent antibody therapeutics by design, Nat. Rev. Immunol., 6, 343, 2006.
2. Pollard, L. and Choy, E., Rheumatoid arthritis: Non-tumor necrosis factor targets, Curr. Opin. Rheumatol., 17, 242, 2005.
3. Puppo, F., et al., Emerging biologic drugs for the treatment of rheumatoid arthritis, Autoimmun. Rev., 4, 537, 2005.
4. Brambell, F.W., The transmission of immunity from mother to young and the catabolism of immunoglobulins, Lancet, 2, 1087, 1966.
5. Manz, R.A., et al., Maintenance of serum antibody levels, Annu. Rev. Immunol., 23, 367, 2005.
6. Roopenian, D.C., et al., The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs, J. Immunol., 170, 3528, 2003.
7. Yoshida, M., et al., Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells, Immunity, 20, 769, 2004.
8. Lencer, W.I. and Blumberg, R.S., A passionate kiss, then run: Exocytosis and recycling of IgG by FcRn, Trends Cell. Biol., 15, 5, 2005.
9. Ghetie, V. and Ward, E.S., Transcytosis and catabolism of antibody, Immunol. Res., 25, 97, 2002.
10. Vaccaro, C., et al., Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels, Nat. Biotechnol., 23, 1283, 2005.
11. Simister, N.E., Placental transport of immunoglobulin G, Vaccine, 21, 3365, 2003.
12. Bonnick, S.L. and Shulman, L., Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both?, Am. J. Med., 119, S25, 2006.
13. Vermeire, S., Van Assche, G., and Rutgeerts, P., Laboratory markers in IBD: Useful, magic, or unnecessary toys?, Gut, 55, 426, 2006.
14. Burczynski, M.E. and Dorner, A.J., Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies, Pharmacogenomics, 7, 187, 2006.
15. Bild, A.H., et al., Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, 439, 353, 2006.
16. Catrina, A.I., et al., Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report, Arthritis Rheum., 52, 61, 2005.
17. Eriksson, C., et al., Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha, Ann. Rheum. Dis., 64, 403, 2005.
18. De Rycke, L., et al., Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy, Arthritis Rheum., 52, 2146, 2005.
19. De Rycke, L., et al., Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis, Arthritis Rheum., 52, 2192, 2005.
20. Kruithof, E., et al., Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies, Arthritis Rheum., 52, 3898, 2005.
21. Buch, M.H., et al., C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept, Arthritis Rheum., 52, 42, 2005.
22. Aeberli, D., et al., Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors, Rheumatology (Oxford), 44, 172, 2005.
23. Jarand, J., et al., Neurological Complications of Infliximab, J. Rheumatol., 2006.
24. Wadman, M., London’s disastrous drug trial has serious side effects for research, Nature, 440, 388, 2006.
25. Self, C.H. and Thompson, S., How specific are therapeutic monoclonal antibodies?, Lancet, 367, 1038, 2006.
26. Mayor, S., Severe adverse reactions prompt call for trial design changes, BMJ, 332, 683, 2006.
27. Mayor, S., Inquiry into adverse events in trial blames drug, not study design, BMJ, 332, 870, 2006.
28. Marshall, E., Clinical medicine. Accident prompts a closer look at antibody trials, Science, 312, 172, 2006.
29. Goodyear, M., Learning from the TGN1412 trial, BMJ, 332, 677, 2006.
30. Hauser, S.L. and Weiner, H.L., Natalizumab: Immune effects and implications for therapy, Ann. Neurol., 59, 731, 2006.
31. Langer-Gould, A. and Steinman, L., Progressive multifocal leukoencephalopathy and multiple sclerosis: Lessons from natalizumab, Curr. Neurol. Neurosci. Rep., 6, 253, 2006.
32. Langer-Gould, A. and Steinman, L., What went wrong in the natalizumab trials?, Lancet, 367, 708, 2006.
33. Stuve, O., et al., Immune surveillance in multiple sclerosis patients treated with natalizumab, Ann. Neurol., 59, 743, 2006.
34. Symmons, D.P. and Silman, A.J., The world of biologics, Lupus, 15, 122, 2006.
35. Nahar, I.K., et al., Infliximab treatment of rheumatoid arthritis and Crohn’s disease, Ann. Pharmacother., 37, 1256, 2003.
36. Listing, J., et al., Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum., 52, 3403, 2005.
37. Slamon, D.J., et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 2001.
38. Vogel, C., et al., First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: A preliminary report, Eur. J. Cancer, 37 (Suppl. 1), S25, 2001.
39. Romond, E.H., et al., Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer, N. Engl. J. Med., 353, 1673, 2005.
40. Tan-Chiu, E., et al., Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31, J. Clin. Oncol., 23, 7811, 2005.
41. Levine, M.N., Trastuzumab cardiac side effects: Only time will tell, J. Clin. Oncol., 23, 7775, 2005.
42. Bryant, J. and Geyer, C.E., Trastuzumab for early breast cancer, Lancet, 367, 728, 2006.
43. Casadevall, N., What is antibody-mediated pure red cell aplasia (PRCA)?, Nephrol. Dial. Transplant, 20 Suppl 4, iv3, 2005.
44. Shinohara, K., et al., Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure, Am. J. Hematol., 78, 15, 2005.
45. Hermeling, S., et al., Reaction to the paper: Interaction of polysorbate 80 with erythropoietin: A case study in protein-surfactant interactions, Pharm. Res., 23, 641, 2006.
46. Casadevall, N., Eckardt, K.U., and Rossert, J., Epoetin-induced autoimmune pure red cell aplasia, J. Am. Soc. Nephrol., 16 (Suppl. 1), S67, 2005.
47. Villalobos, A.P., Gunturi, S.R., and Heavner, G.A., Interaction of polysorbate 80 with erythropoietin: A case study in protein-surfactant interactions, Pharm. Res., 22, 1186, 2005.
48. Rossert, J., Erythropoietin-induced, antibody-mediated pure red cell aplasia, Eur. J. Clin. Invest., 35 Suppl 3, 95, 2005.
49. Ghetie, V. and Ward, E.S., Multiple roles for the major histocompatibility complex class I- related receptor FcRn, Annu. Rev. Immunol., 18, 739, 2000.
50. Lamanna, N., et al., Pentostatin, cyclophosphamide, and rituximab is an active, welltolerated regimen for patients with previously treated chronic lymphocytic leukemia, J. Clin. Oncol., 24, 1575, 2006.
51. Lamanna, N., Advances in the treatment of chronic lymphocytic leukemia, Curr. Oncol. Rep., 7, 333, 2005.
52. Kashmiri, S.V., et al., SDR grafting - a new approach to antibody humanization, Methods, 36, 25, 2005.
53. Hwang, W.Y., et al., Use of human germline genes in a CDR homology-based approach to antibody humanization, Methods, 36, 35, 2005.
54. Presta, L.G., Selection, design, and engineering of therapeutic antibodies, J. Allergy Clin. Immunol., 116, 731, 2005.
55. Hwang, W.Y. and Foote, J., Immunogenicity of engineered antibodies, Methods, 36, 3, 2005.
56. Rathanaswami, P., et al., Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8, Biochem. Biophys. Res. Commun., 334, 1004, 2005.
57. Neuberger, M., Generating high-avidity human Mabs in mice, Nat. Biotechnol., 14, 826, 1996.
58. Lonberg, N., Human antibodies from transgenic animals, Nat. Biotechnol., 23, 1117, 2005.
59. Kyewski, B. and Klein, L., A central role for central tolerance, Annu. Rev. Immunol., 24, 571, 2006.
60. Ferry, H., et al., B-cell tolerance, Transplantation, 81, 308, 2006.
61. Mamula, M.J., Farber, D.L., and Tsokos, G.C., Autoimmune odyssey on the Aegean Sea, Nat. Immunol., 7, 219, 2006.
62. Lim, P.L. and Zouali, M., Pathogenic autoantibodies: Emerging insights into tissue injury, Immunol. Lett., 103, 17, 2006.
63. Schaffitzel, C., et al., Ribosome display: An in vitro method for selection and evolution of antibodies from libraries, J. Immunol. Methods, 231, 119, 1999.
64. Hoogenboom, H.R., Selecting and screening recombinant antibody libraries, Nat. Biotechnol., 23, 1105, 2005.
65. Hoet, R.M., et al., Generation of high-affinity human antibodies by combining donorderived and synthetic complementarity-determining-region diversity, Nat. Biotechnol., 23, 344, 2005.
66. Carmen, S. and Jermutus, L., Concepts in antibody phage display, Brief Funct. Genomic Proteomic, 1, 189, 2002.
67. Jermutus, L., Phage Display Technologies - SMi Conference. 23-24 January 2002, London, U.K., IDrugs, 5, 203, 2002.
68. Groves, M.A. and Osbourn, J.K., Applications of ribosome display to antibody drug discovery, Expert Opin. Biol. Ther., 5, 125, 2005.
69. Lennard, S., Standard protocols for the construction of scFv libraries, Methods Mol. Biol., 178, 59, 2002.
70. Jostock, T., et al., Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries, J. Immunol. Methods, 289, 65, 2004.
71. Hanes, J., et al., Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries, Proc. Natl. Acad. Sci. USA, 95, 14130, 1998.
72. Tamaoka, A., et al., Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Neurobiol. Aging, 17, 405, 1996.
73. Liu, B., et al., Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: Cautions on evaluating p170(mdr-1), J. Natl. Cancer Inst., 89, 1524, 1997.
74. Schuermann, J.P., et al., Structure of an anti-DNA fab complexed with a non-DNA ligand provides insights into cross-reactivity and molecular mimicry, Proteins, 57, 269, 2004.
75. Spellerberg, M.B., et al., Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: A possible link between infection and lupus, Hum. Antibodies Hybridomas, 6, 52, 1995.
76. Otte, L., et al., Molecular basis for the binding polyspecificity of an anti-cholera toxin peptide 3 monoclonal antibody, J. Mol. Recognit., 19, 49, 2006.
77. Xu, Y., et al., Two monoclonal antibodies to precisely the same epitope of type II collagen select non-crossreactive phage clones by phage display: Implications for autoimmunity and molecular mimicry, Mol. Immunol., 41, 411, 2004.
78. Geylis, V., et al., Human monoclonal antibodies against amyloid-beta from healthy adults, Neurobiol. Aging, 26, 597, 2005.
79. Czompoly, T., et al., A possible new bridge between innate and adaptive immunity: Are the anti-mitochondrial citrate synthase autoantibodies components of the natural antibody network?, Mol. Immunol., 43, 1761, 2006.
80. Franchini, M., et al., Acquired hemophilia A: A concise review, Am. J. Hematol., 80, 55, 2005.
81. Fleming, S.D. and Tsokos, G.C., Complement, natural antibodies, autoantibodies and tissue injury, Autoimmun. Rev., 5, 89, 2006.
82. Zhang, M., et al., Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury, Proc. Natl. Acad. Sci. USA, 101, 3886, 2004.
83. Zhu, X., et al., Cofactor-containing antibodies: Crystal structure of the original yellow antibody, Proc. Natl. Acad. Sci. USA, 103, 3581, 2006.
84. Nieva, J., et al., Immunoglobulins can utilize riboflavin (Vitamin B2) to activate the antibody-catalyzed water oxidation pathway, Immunol. Lett., 103, 33, 2006.
85. Sendi, P., et al., Intranasal influenza vaccine in a working population, Clin. Infect. Dis., 38, 974, 2004.
86. de Bruijn, I.A., et al., Clinical experience with inactivated, virosomal influenza vaccine, Vaccine, 23 (Suppl. 1), S39, 2005.
87. De Serres, G., et al., Oculo-respiratory syndrome after influenza vaccination: Trends over four influenza seasons, Vaccine, 23, 3726, 2005.
88. Ebringer, A. and Rashid, T., Rheumatoid arthritis is an autoimmune disease triggered by Proteus urinary tract infection, Clin. Dev. Immunol., 13, 41, 2006.
89. Chiavaroli, C. and Moore, A., An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis, BioDrugs, 20, 141, 2006.
90. Soderberg-Naucler, C., Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?, J. Intern. Med., 259, 219, 2006.
91. Anders, H.J., et al., Molecular mechanisms of autoimmunity triggered by microbial infection, Arthritis Res. Ther, 7, 215, 2005.
92. Patole, P.S., et al., Viral double-stranded RNA aggravates lupus nephritis through Tolllike receptor 3 on glomerular mesangial cells and antigen-presenting cells, J. Am. Soc. Nephrol., 16, 1326, 2005.
93. Perosa, F., et al., Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor, Blood, 107, 1070, 2006.
94. Binder, M., et al., The epitope recognized by rituximab, Blood, 2006.
95. Polyak, M.J. and Deans, J.P., Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure, Blood, 99, 3256, 2002.
96. Preissner, R., et al., Inverse sequence similarity in proteins and its relation to the threedimensional fold, FEBS Lett., 414, 425, 1997.
97. Menendez, A. and Scott, J.K., The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies, Anal. Biochem., 336, 145, 2005.
98. Tabrizi, M.A., Tseng, C.M., and Roskos, L.K., Elimination mechanisms of therapeutic monoclonal antibodies, Drug Discov. Today, 11, 81, 2006.
99. Rogers, A.B., Cormier, K.S., and Fox, J.G., Thiol-reactive compounds prevent nonspecific antibody binding in immunohistochemistry, Lab. Invest., 86, 526, 2006.
100. Michaud, G.A., et al., Analyzing antibody specificity with whole proteome microarrays, Nat. Biotechnol., 21, 1509, 2003.
101. Merkel, J.S., et al., Functional protein microarrays: Just how functional are they?, Curr. Opin. Biotechnol., 16, 447, 2005.
102. Bangham, R., et al., Protein microarray-based screening of antibody specificity, Methods Mol. Med., 114, 173, 2005.
103. Predki, P.F., et al., Protein microarrays: A new tool for profiling antibody crossreactivity, Hum. Antibodies, 14, 7, 2005.
104. Boscolo, S., et al., Detection of anti-brain serum antibodies using a semi-quantitative immunohistological method, J. Immunol. Methods, 309, 139, 2006.
105. McIntyre, J.A., Wagenknecht, D.R., and Faulk, W.P., Redox-reactive autoantibodies: Detection and physiological relevance, Autoimmun. Rev., 5, 76, 2006.
106. McIntyre, J.A., Wagenknecht, D.R., and Faulk, W.P., Autoantibodies unmasked by redox reactions, J. Autoimmun., 24, 311, 2005.
107. McIntyre, J.A., The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation - reduction reactions, Thromb. Res., 114, 579, 2004.
108. Agrawal, S., Misra, R., and Aggarwal, A., Autoantibodies in rheumatoid arthritis: Association with severity of disease in established RA, Clin. Rheumatol., 2006.
109. Ates, A., Karaaslan, Y., and Aksaray, S., Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis, Clin. Rheumatol., 2006.
110. Caspi, D., et al., Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis, Arthritis Rheum., 55, 53, 2006.
111. Sihvonen, S., et al., The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis, J. Rheumatol., 32, 2089, 2005.
112. Vander Cruyssen, B., et al., Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: Specificity and relation with rheumatoid factor, Autoimmun. Rev., 4, 468, 2005.
113. Zhang, M., et al., Identification of the target self-antigens in reperfusion injury, J Exp Med, 203, 141, 2006.
114. Westall, F.C., Molecular mimicry or structural mimicry?, Mol. Immunol., 43, 1062, 2006.
115. Etienne, M. and Weimer, L.H., Immune-mediated autonomic neuropathies, Curr. Neurol. Neurosci. Rep., 6, 57, 2006.
116. Hill, P.G. and McMillan, S.A., Anti-tissue transglutaminase antibodies and their role in the investigation of coeliac disease, Ann. Clin. Biochem., 43, 105, 2006.
117. Agrup, C. and Luxon, L.M., Immune-mediated inner-ear disorders in neuro-otology, Curr. Opin. Neurol., 19, 26, 2006.
118. Greidinger, E.L., et al., A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen, Arthritis Rheum., 54, 661, 2006.
119. Fujii, T., The mechanisms of antinuclear antibody production and its pathogenicity in systemic autoimmune diseases, Nihon Rinsho Meneki Gakkai Kaishi, 29, 57, 2006.
120. Ganor, Y., et al., Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon’s syndrome, Autoimmunity, 38, 417, 2005.
121. Ganor, Y., et al., Autoimmune epilepsy: Distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA, Epilepsy Res., 65, 11, 2005.
122. Husebye, E.S., et al., Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus, Ann. Rheum. Dis., 64, 1210, 2005.
123. Fathman, C.G., et al., An array of possibilities for the study of autoimmunity, Nature, 435, 605, 2005.
124. Robinson, W.H., Antigen arrays for antibody profiling, Curr. Opin. Chem. Biol., 10, 67, 2006.
125. Robinson, W.H., et al., Autoantigen microarrays for multiplex characterization of autoantibody responses, Nat. Med., 8, 295, 2002.
126. Wang, X.P., et al., Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: A janus-faced antigen, J. Am. Soc. Nephrol., 16, 3563, 2005.
127. Wang, X., et al., Autoantibody signatures in prostate cancer, N. Engl. J. Med., 353, 1224, 2005.
128. Du, H., et al., The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with earlystage knee osteoarthritis: Evidence of a variety of autoimmune processes, Rheumatol. Int., 26, 35, 2005.
129. Trebst, C. and Stangel, M., Promotion of remyelination by immunoglobulins: Implications for the treatment of multiple sclerosis, Curr. Pharm. Des., 12, 241, 2006.
130. Bayary, J., et al., Intravenous immunoglobulin in autoimmune disorders: An insight into the immunoregulatory mechanisms, Int. Immunopharmacol., 6, 528, 2006.
131. Oppenheim, J.J., et al., Autoantigens act as tissue-specific chemoattractants, J. Leukoc. Biol., 77, 854, 2005.
132. Yasuda, S., et al., Pathogenesis of antiphospholipid antibodies: Impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway, Immunobiology, 210, 775, 2005.
133. Matsubayashi, H., et al., IgG-Antiphospholipid antibodies in follicular fluid of IVF-ET patients are related to low fertilization rate of their oocytes, Am. J. Reprod. Immunol., 55, 341, 2006.
134. Borza, D.B., et al., Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: Novel mechanisms for immune privilege and autoimmune pathogenesis, J. Biol. Chem., 280, 27147, 2005.
135. Chan, R.K., et al., Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM, Surgery, 139, 236, 2006.
136. Howard, O.M., et al., Autoantigens signal through chemokine receptors: Uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate, Blood, 105, 4207, 2005.
137. Hinagata, J., et al., Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model, Cardiovasc. Res., 69, 263, 2006.
138. Awadallah, S.M., et al., Autoantibodies against oxidized LDL correlate with serum concentrations of ceruloplasmin in patients with cardiovascular disease, Clin. Chim. Acta, 365, 330, 2006.
139. Resch, U., et al., Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy, Br. J. Clin. Pharmacol., 61, 262, 2006.
140. Nimmerjahn, F. and Ravetch, J.V., Fcgamma receptors: Old friends and new family members, Immunity, 24, 19, 2006.
141. Tsuchiya, N. and Kyogoku, C., Role of Fc gamma receptor IIb polymorphism in the genetic background of systemic lupus erythematosus: Insights from Asia, Autoimmunity, 38, 347, 2005.
142. Akilesh, S., et al., The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease, J. Clin. Invest., 113, 1328, 2004.
143. Li, N., et al., Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases, J. Clin. Invest., 115, 3440, 2005.
144. Geylis, V. and Steinitz, M., Immunotherapy of Alzheimer’s disease (AD): From murine models to anti-amyloid beta (Abeta) human monoclonal antibodies, Autoimmun. Rev., 5, 33, 2006.
145. Tsai, M.H., et al., Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin, J. Pediatr., 148, 38, 2006.
146. Stiehm, E.R., Lessons from Kawasaki disease: All brands of IVIG are not equal, J. Pediatr., 148, 6, 2006.
147. Robinson, W.H., et al., Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis, Nat. Biotechnol., 21, 1033, 2003.
148. Hueber, W., et al., Autoantibody profiling for the study and treatment of autoimmune disease, Arthritis Res., 4, 290, 2002.
149. Balboni, I., et al., Multiplexed protein array platforms for analysis of autoimmune diseases, Annu. Rev. Immunol., 24, 391, 2006.
150. Borza, D.B., et al., Recurrent Goodpasture’s disease secondary to a monoclonal IgA1- kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen, Am. J. Kidney Dis., 45, 397, 2005.
151. van Gaalen, F., et al., The devil in the details: The emerging role of anticitrulline autoimmunity in rheumatoid arthritis, J. Immunol., 175, 5575, 2005.
152. Huizinga, T.W., et al., Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins, Arthritis Rheum., 52, 3433, 2005.
153. Lam, A., Toma, W., and Schlesinger, N., Mycobacterium marinum arthritis mimicking rheumatoid arthritis, J. Rheumatol., 33, 817, 2006.
154. Gompels, L.L., et al., Single-blind randomized trial of combination antibiotic therapy in rheumatoid arthritis, J. Rheumatol., 33, 224, 2006.
155. Mimura, Y., et al., Rheumatoid factor isotypes in mixed connective tissue disease, Clin. Rheumatol., 1, 2006.
156. Frohman, E.M., Racke, M.K., and Raine, C.S., Multiple sclerosis - the plaque and its pathogenesis, N. Engl. J. Med., 354, 942, 2006.
157. Kanter, J.L., et al., Lipid microarrays identify key mediators of autoimmune brain inflammation, Nat. Med., 12, 138, 2006.
158. Lalive, P.H., et al., Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis, Proc. Natl. Acad. Sci. USA, 103, 2280, 2006.
159. Schlessinger, A., et al., Epitome: Database of structure-inferred antigenic epitopes, Nucleic Acids Res., 34, D777, 2006.
160. Routsias, J.G., Vlachoyiannopoulos, P.G., and Tzioufas, A.G., Autoantibodies to intracellular autoantigens and their B-cell epitopes: Molecular probes to study the autoimmune response, Crit. Rev. Clin. Lab. Sci., 43, 203, 2006.
161. Fontoura, P. and Steinman, L., Nogo in multiple sclerosis: Growing roles of a growth inhibitor, J. Neurol. Sci., 2006.
162. Gianani, R., et al., Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies, J. Clin. Endocrinol. Metab., 91, 1855, 2006.
163. Pietropaolo, M. and Eisenbarth, G.S., Autoantibodies in human diabetes, Curr. Dir. Autoimmun., 4, 252, 2001.
164. Fourlanos, S., et al., A clinical screening tool identifies autoimmune diabetes in adults, Diabetes Care, 29, 970, 2006.
165. Nesterova, M., et al., Autoantibody biomarker opens a new gateway for cancer diagnosis, Biochim. Biophys. Acta, 1762, 398, 2006.
166. Cho-Chung, Y.S., Autoantibody biomarkers in the detection of cancer, Biochim. Biophys. Acta, 1762, 587, 2006.
167. Bradford, T.J., Wang, X., and Chinnaiyan, A.M., Cancer immunomics: Using autoantibody signatures in the early detection of prostate cancer, Urol. Oncol., 24, 237, 2006.
168. Mooney, C.J., et al., Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis, Int. J. Urol., 13, 211, 2006.